10-Q: Organogenesis Q2 2025: Revenue Plunges Amid Regulatory Uncertainty

Organogenesis Holdings Inc. reported a significant decline in Q2 2025 revenue and a widened net loss, primarily driven by regulatory ambiguity in the advanced wound care market.

Summary

• Net product revenue for the six months ended June 30, 2025, decreased by $52.7 million, or 22%, to $187.5 million, compared to $240.2 million in the prior year period.
• Advanced Wound Care product revenue decreased by $54.5 million, or 24%, to $172.6 million for the six months ended June 30, 2025, attributed to customer disruption from delayed Local Coverage Determinations (LCDs).
• Surgical & Sports Medicine product revenue increased by $1.7 million, or 13%, to $14.8 million for the six months ended June 30, 2025.
• Net loss for the six months ended June 30, 2025, widened to $28.2 million, compared to a net loss of $19.1 million in the same period last year.
• Adjusted EBITDA for the six months ended June 30, 2025, was a negative $16.2 million, a substantial decrease from a positive $18.2 million in the prior year period.
• Cash and cash equivalents decreased significantly to $73.1 million as of June 30, 2025, from $135.6 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, increased to $52.8 million, compared to $5.4 million in the prior year period.
• The company recorded an $8.3 million write-down for an asset held for sale during the six months ended June 30, 2025.
• Shareholders approved the conversion of Series A Convertible Preferred Stock in excess of Nasdaq Ownership Limitations during Q2 2025.

Sentiment

Score: 3

Explanation: The significant decline in revenue, widening net loss, negative Adjusted EBITDA, and substantial cash burn from operations indicate a challenging financial period. While some legal uncertainties have been resolved and a grant received, the ongoing regulatory risks and the need to renegotiate credit agreement covenants present considerable headwinds. The outlook for Dermagraft is long-term, but the immediate impact of LCD delays on key products is negative.

Positives

• Surgical & Sports Medicine net product revenue increased by 13% to $14.8 million for the six months ended June 30, 2025, indicating growth in this segment.
• The False Claims Act complaint against the company was dismissed without prejudice on May 19, 2025, resolving a legal uncertainty.
• Secured a $5.0 million grant from a governmental agency for the Smithfield Facility, with $2.5 million cash received in Q2 2025.
• Shareholder approval for the conversion of Convertible Preferred Stock removes previous limitations on conversion.

Negatives

• Total net product revenue decreased by 22% for the six months ended June 30, 2025, primarily due to a 24% decline in Advanced Wound Care revenue.
• Net loss widened to $28.2 million for the six months ended June 30, 2025, from $19.1 million in the prior year.
• Adjusted EBITDA turned negative, falling to $(16.2) million for the six months ended June 30, 2025, from $18.2 million in the prior year.
• Cash and cash equivalents decreased by over $62 million in the first six months of 2025, indicating significant cash burn.
• Net cash used in operating activities increased substantially to $52.8 million for the six months ended June 30, 2025, from $5.4 million in the prior year.
• Gross profit decreased by 25% for the six months ended June 30, 2025, due to decreased sales volume and a shift in product mix.
• The company recorded an $8.3 million write-down for an asset held for sale during the six months ended June 30, 2025, reflecting a loss on property value.

Risks

• Significant delays in the build-out of the Smithfield Facility or in FDA approval for Dermagraft manufacturing could adversely affect future net product revenue and results of operations.
• The new Local Coverage Determinations (LCDs), if implemented on January 1, 2026, would classify over 200 products (including PuraPly, Novachor, Dual, and Matrix) as non-covered for DFUs and VLUs, potentially materially impacting utilization, business, and revenue.
• Uncertainty exists regarding further delays, revisions, or rescission of the new LCDs, creating ongoing market ambiguity.
• CMS proposed rules for 2026, which suggest changes to Medicare payments for skin substitute products, could materially impact product utilization, business, and revenue.
• Failure to enter into an agreement to reset or implement new financial covenants for the 2021 Credit Agreement by September 30, 2025, would constitute an event of default.
• Lenders have no further obligation to make revolving extensions of credit under the 2021 Credit Agreement until a new agreement on financial covenants is executed.
• There is no assurance that additional funds, if necessary for long-term liquidity, will be obtained on acceptable terms, on a timely basis, or at all.

Future Outlook

The company plans to transition Dermagraft manufacturing to its new Smithfield, Rhode Island biomanufacturing facility, expecting to begin in 2027 and resume sales by the end of 2027, which is anticipated to result in substantial long-term cost savings. Management expects cash on hand and working capital, combined with net cash flows from product sales, to be sufficient to fund operating expenses, capital expenditures, and debt service for at least 12 months beyond the filing date. However, the implementation of new Local Coverage Determinations (LCDs) on January 1, 2026, and proposed CMS policy changes for 2026, could materially impact product utilization and revenue. The company is also required to agree on new financial covenants for its 2021 Credit Agreement by September 30, 2025, to avoid an event of default and ensure continued access to revolving credit.

Management Comments

• We expect that our cash on hand and other components of working capital as of June 30, 2025, plus net cash flows from product sales will be sufficient to fund our operating expenses, capital expenditure requirements and debt service payments for at least 12 months beyond the filing date of this Form 10-Q.
• While we believe CMS proposed payment structure will curb abuse under the current system, and the resulting rapid escalation in Medicare spending, and ensure a much-needed consistent payment approach across sites of care, the changes could also materially impact utilization of our products, our business, and our revenue.

Industry Context

The regenerative medicine and advanced wound care industry is highly sensitive to regulatory and reimbursement changes, particularly from Medicare. The ongoing delays and potential implementation of new Local Coverage Determinations (LCDs) and proposed CMS rules create significant uncertainty for companies like Organogenesis. These changes could reshape market access and coverage for a wide range of skin substitute products, favoring those with specific FDA regulatory statuses (PMA, 510(k)) and potentially disadvantaging others (361 HCT/Ps). The shift towards a single payment rate for skin substitutes in 2026, with future differentiation, aims to curb Medicare spending and incentivize innovation but poses a material risk to companies whose product portfolios are heavily impacted by non-coverage classifications. Organogenesis's strategy to consolidate manufacturing and focus on FDA-approved products like Apligraf and Dermagraft (post-relaunch) aligns with adapting to these evolving regulatory landscapes, but the immediate disruption is evident in its Advanced Wound Care revenue decline.

Legal Proceedings

• A complaint captioned United States of America, State of Texas, ex rel. John Doe vs. Organogenesis Holdings, Inc., filed in the United States District Court for the Southern District of Texas, was dismissed without prejudice on May 19, 2025. The complaint alleged claims pursuant to the United States False Claims Act and the Texas State Medicaid Fraud Prevention Act.

Related Party Transactions

• Lease obligations to affiliates (65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC) for office and laboratory space in Canton, Massachusetts.
• In November 2024, the company repurchased 7,921,731 shares of Class A common stock from certain existing stockholders, including directors and their affiliates.

Stakeholder Impact

• **Shareholders:** Negative impact due to significant revenue decline, increased net loss, negative Adjusted EBITDA, and substantial cash burn, which could lead to share price depreciation. Potential for future dilution if capital raise involves equity.
• **Employees:** Potential impact from operational adjustments due to revenue decline and strategic shifts, though no specific workforce changes were detailed.
• **Customers:** Disruption and ambiguity in customer behavior in the Advanced Wound Care market due to delayed and uncertain regulatory changes (LCDs) could affect product access and choices.
• **Lenders:** The requirement to reset financial covenants by September 30, 2025, and the suspension of revolving credit extensions until then, indicate increased scrutiny and potential for renegotiation of debt terms.
• **Suppliers:** Decreased sales volume could lead to reduced demand for raw materials and manufacturing components.

Next Steps

• Resume sales of Dermagraft by the end of 2027, following the transition of manufacturing to the Smithfield Facility.
• Enter into an agreement with lenders to reset or implement new financial covenants for the 2021 Credit Agreement prior to September 30, 2025.
• Continue evaluating the impact of adopting new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05) on consolidated financial statements.
• Monitor and adapt to the potential implementation of new Local Coverage Determinations (LCDs) on January 1, 2026.
• Evaluate the future impact of the One Big Beautiful Bill Act (OBBBA) tax law changes on condensed consolidated financial statements.
• Continue build-out of the Smithfield, Rhode Island facility, expected to be completed in fiscal 2027.

Key Dates

Recommendation

The filing reveals a significant deterioration in financial performance, with a 22% decline in net product revenue, a widened net loss, and a shift to negative Adjusted EBITDA for the first half of 2025. The substantial increase in cash used in operating activities indicates a high cash burn rate, leading to a significant reduction in cash and cash equivalents. The primary driver for these negative results is the ongoing regulatory uncertainty surrounding Medicare Local Coverage Determinations (LCDs), which have been repeatedly delayed and, if implemented, would classify a large portion of the company's product portfolio as non-covered. This regulatory risk, coupled with the need to renegotiate credit agreement covenants by September 30, 2025, and the potential for future capital raises, creates a highly uncertain and unfavorable investment environment. While the Surgical & Sports Medicine segment showed growth and a legal proceeding was dismissed, these positives are overshadowed by the broader financial and regulatory challenges. A seasoned investor would likely view these results and outlook as a strong signal to reduce exposure.

Keywords

Regenerative Medicine, Wound Care, SEC Filing, 10-Q, Organogenesis, ORGO, Advanced Wound Care, Surgical & Sports Medicine, Medicare, CMS, LCDs, Dermagraft, Apligraf, PuraPly, Financial Results, Biotechnology, Medical Devices